A role for EMT in CD73 regulation in breast cancer
CD73 is an emerging target in cancer due to its role in generating adenosine, a potent immunosuppressor. We found that SNAI1, a driver of epithelial-to-mesenchymal transition (EMT), upregulates CD73 in triple negative breast cancer cells. Here, we discuss the relevance of improving CD73-based therap...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2152636 |
| _version_ | 1811213656677941248 |
|---|---|
| author | Meriem Hasmim Guy Berchem Bassam Janji |
| author_facet | Meriem Hasmim Guy Berchem Bassam Janji |
| author_sort | Meriem Hasmim |
| collection | DOAJ |
| description | CD73 is an emerging target in cancer due to its role in generating adenosine, a potent immunosuppressor. We found that SNAI1, a driver of epithelial-to-mesenchymal transition (EMT), upregulates CD73 in triple negative breast cancer cells. Here, we discuss the relevance of improving CD73-based therapy by combining with inhibitors of EMT. |
| first_indexed | 2024-04-12T05:49:56Z |
| format | Article |
| id | doaj.art-c23e26de533c482294c3b7e2948b5915 |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-04-12T05:49:56Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-c23e26de533c482294c3b7e2948b59152022-12-22T03:45:20ZengTaylor & Francis GroupOncoImmunology2162-402X2022-12-0111110.1080/2162402X.2022.2152636A role for EMT in CD73 regulation in breast cancerMeriem Hasmim0Guy Berchem1Bassam Janji2Tumor Immunotherapy and Microenvironment Group, Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, LuxembourgTumor Immunotherapy and Microenvironment Group, Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, LuxembourgTumor Immunotherapy and Microenvironment Group, Department of Cancer Research, Luxembourg Institute of Health (LIH), Luxembourg City, LuxembourgCD73 is an emerging target in cancer due to its role in generating adenosine, a potent immunosuppressor. We found that SNAI1, a driver of epithelial-to-mesenchymal transition (EMT), upregulates CD73 in triple negative breast cancer cells. Here, we discuss the relevance of improving CD73-based therapy by combining with inhibitors of EMT.https://www.tandfonline.com/doi/10.1080/2162402X.2022.2152636CD73SNAI1epithelial-to-mesenchymal transitionadenosinetriple negative breast cancerimmunotherapy |
| spellingShingle | Meriem Hasmim Guy Berchem Bassam Janji A role for EMT in CD73 regulation in breast cancer OncoImmunology CD73 SNAI1 epithelial-to-mesenchymal transition adenosine triple negative breast cancer immunotherapy |
| title | A role for EMT in CD73 regulation in breast cancer |
| title_full | A role for EMT in CD73 regulation in breast cancer |
| title_fullStr | A role for EMT in CD73 regulation in breast cancer |
| title_full_unstemmed | A role for EMT in CD73 regulation in breast cancer |
| title_short | A role for EMT in CD73 regulation in breast cancer |
| title_sort | role for emt in cd73 regulation in breast cancer |
| topic | CD73 SNAI1 epithelial-to-mesenchymal transition adenosine triple negative breast cancer immunotherapy |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2152636 |
| work_keys_str_mv | AT meriemhasmim aroleforemtincd73regulationinbreastcancer AT guyberchem aroleforemtincd73regulationinbreastcancer AT bassamjanji aroleforemtincd73regulationinbreastcancer AT meriemhasmim roleforemtincd73regulationinbreastcancer AT guyberchem roleforemtincd73regulationinbreastcancer AT bassamjanji roleforemtincd73regulationinbreastcancer |